Drug products: Avopenin, Fenoximetylpenicillin EQL Pharma, Fenoximetylpenicillin Orifarm, Kåvepenin®, Kåvepenin® Frukt, Peceve®, Phenoxymethylpenicillin EQL, Primve, Tikacillin
ATC code: J01CE02
Controlled studies on differences between men and women regarding the effect, safety and pharmacokinetics of phenoxymethylpenicillin are lacking. A smaller study indicates that exposure of phenoxymethylpenicillin during pregnancy can be lower than in non-pregnant women, and dose adjustment thus can be needed.
Pharmacokinetics and dosing
A pharmacokinetic study described changes in phenoxymethylpenicillin pharmacokinetics during pregnancy (12 pregnant women, 6 non-pregnant controls), in comparison to non-pregnancy. Following a single dose, half-life was shorter during the third trimester compared to the non-pregnant state. Also, exposure was lower for women in the second trimester of pregnancy than for non-pregnant women. These findings indicate increased elimination of phenoxymethylpenicillin during mid and late pregnancy, although differences in elimination were non-significant. The authors recommend reduced dosing-interval or increased dose of phenoxymethylpenicillin in pregnant women .
No studies with a clinically relevant sex analysis regarding the effect of phenoxymethylpenicillin have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of phenoxymethylpenicillin have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2021-01-11
Reviewed by: Diana Rydberg
Approved by: Karin Schenck-Gustafsson